Nilutamide

small molecule

Identifier: CI-DRUG-00000405
Entity page: /drug/nilutamide ↗
Edges: 24

Neighbours: 5 cancers1 genes1 variants10 trials6 approvals
Drawn: 23 of 23 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Nilutamide approved for …APPROVED_FOR7 of 6
→ approved for	Malignant Prostate Neoplasmcancer	supports	FDA ORIG	Malignant Prostate Neoplasm	1	Regulatory	openfda	graph →
→ approved for	Health Canada · CA · 1997Marketed in Canada as ANANDRON (DIN 02221861) under ATC L02BB02 NILUTAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Nilutamide predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	AR Mutationother	resistance	B	Malignant Prostate Neoplasm	1	Curated	civic	graph →

Nilutamide predicts response to …PREDICTS_RESPONSE_TO1 of 1

← predicts response to

AR Mutationother

resistance

Malignant Prostate Neoplasm

Curated

Nilutamide investigated for …INVESTIGATED_FOR3 of 3
→ investigated for	Malignant Prostate Neoplasmcancer	supports	B	Malignant Prostate Neoplasm	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Prostate Neoplasmsubtype	unknown	4	Prostate Neoplasm	1	Curated	chembl	graph →

Nilutamide investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Malignant Prostate Neoplasmcancer 8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Adenocarcinoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →

Nilutamide studied in …STUDIED_INderived10 of 10
→ studied in	NCT03070886Phase 2/Phase 3 · active not recruiting Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery · 10 trials list this drug (3 active)	—	—	Prostate Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01786265Phase 2 · active not recruiting Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer · 10 trials list this drug (3 active)	—	—	Prostate Adenocarcinoma,Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03678025Phase 3 · recruiting Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00003653Phase 3 · completed Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00002633Phase 3 · completed Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00002855Phase 3 · completed Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00020254Phase 2 · completed Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00918385Phase 2 · terminated Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00028769Phase 2 · completed S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer · 10 trials list this drug (3 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00512668Phase 1 · terminated Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer · 10 trials list this drug (3 active)	—	—	Prostate Adenocarcinoma,Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths